Key result
Dabigatran 225 mg cuts DVT risk ~21% vs. enoxaparin.
Why the study?
Novel oral anticoagulants are increasingly prescribed after surgery to prevent thromboembolism, but the comparative efficacy and safety of dabigatran versus enoxaparin for thromboprophylaxis following total hip replacement required evaluation.
Does dabigatran reduce the risk of venous thromboembolism and bleeding events compared to enoxaparin for thromboprophylaxis following total hip replacement?
Meta-Analysis (n=9,538)
Yes
Does dabigatran reduce the risk of venous thromboembolism and bleeding events compared to enoxaparin for thromboprophylaxis following total hip replacement?
Dabigatran is an effective and safe alternative to enoxaparin for thromboprophylaxis after total hip replacement, with the 225 mg dose potentially offering superior VTE reduction without increased bleeding risk.
Supports dabigatran 225 mg over enoxaparin for thromboprophylaxis after total hip replacement; extends evidence for NOAC superiority in VTE prevention.
Novel oral anticoagulants (NOACs) are now more often being prescribed following surgery to reduce the risk of thromboembolism. In this analysis we aimed to compare dabigatran with enoxaparin for thromboprophylaxis following total hip replacement (THR). Online databases were searched for studies solely comparing dabigatran with enoxaparin for thromboprophylaxis following THR. Relevant studies were finalized after carefully assessing the titles and abstracts. The clinical outcomes including outcomes of efficacy and safety were considered as the endpoints. The updated version of RevMan software was used to carry out this statistical analysis. Risk ratios (RR) with 95% confidence intervals (CIs) were used to represent the results. A total number of 4 studies including 6168 participants were assigned to dabigatran following THR whereas 3370 participants were assigned to enoxaparin resulting in a total number of 9538 participants which were included in this analysis. The time frame for participants’ enrollment varied from year 2002 to year 2012. Results of this analysis showed that when dabigatran was compared with enoxaparin following THR, deep venous thrombosis (DVT) (RR: 0.97, 95% CI: 0.80 – 1.18; P = 0.77), venous thromboembolism (VTE) (RR: 0.92, 95% CI: 0.70 – 1.19; P = 0.51) and pulmonary embolism (RR: 0.83, 95% CI: 0.25 – 2.71; P = 0.76) were similarly manifested. In addition, major bleeding (RR: 1.25, 95% CI: 0.85 – 1.84; P = 0.26), fatal bleeding (RR: 2.50, 95% CI: 1.12 – 52.03; P = 0.55), minor bleeding (RR: 1.08, 95% CI: 0.89 – 1.32; P = 0.44), bleeding in a critical organ (RR: 2.98, 95% CI: 0.12 – 73.05; P = 0.50) and bleeding requiring blood transfusion (RR: 1.11, 95% CI: 0.77 – 1.59; P = 0.58) were still similarly manifested. However, when dabigatran 225 mg dosage was compared with enoxaparin, the risks for DVT (RR: 0.79, 95% CI: 0.63 – 1.00; P = 0.05) and VTE (RR: 0.65, 95% CI: 0.46 – 0.92; P = 0.02) were significantly lower with dabigatran without any increase in bleeding events. It can be concluded that the NOAC dabigatran was equally effective compared to enoxaparin for thrombo-prophylaxis following THR. No significant thrombotic event was observed with dabigatran when compared to enoxaparin. However, a higher dosage of dabigatran was associated with significantly reduced DVT and VTE. Nevertheless, due to the several limitations of this analysis, the bleeding outcomes were inconclusive and therefore, the results should be confirmed in further newer studies.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) conducted a meta-analysis in Thromboprophylaxis following total hip replacement (n=9,538). Dabigatran vs. Enoxaparin was evaluated on Deep venous thrombosis (DVT) (RR 0.79, 95% CI 0.63 – 1.00, p=0.05). Dabigatran 225 mg significantly reduced the risk of deep venous thrombosis by 21% compared to enoxaparin with an RR of 0.79.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: